2. Search Result
Search Result
Results for "

P450 2C19

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

2

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Natural
Products

6

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17356
    Fenofibrate
    Maximum Cited Publications
    33 Publications Verification

    		 PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate
  • HY-B1184A
    (S)-Mephenytoin

    (+)-Mephenytoin

    		 Cytochrome P450 Neurological Disease
    (S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism .
    (S)-Mephenytoin
  • HY-B0258
    Gemfibrozil
    5+ Cited Publications

    CI-719

    		 PPAR Cytochrome P450 Cardiovascular Disease Metabolic Disease Cancer
    Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil
  • HY-W011235
    Norfluoxetine hydrochloride

    		5-HT Receptor Calcium Channel Drug Metabolite Cardiovascular Disease Neurological Disease
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .
    Norfluoxetine hydrochloride
  • HY-N5132
    (-)-Fenchone

    		Cytochrome P450 Others
    (-)-Fenchone is a bicyclic monoterpene and serves as a substrate for human liver microsomal cytochrome P450 enzymes CYP2A6 and CYP2B6. (-)-Fenchone is not metabolized by human CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzymes. (-)-Fenchone undergoes hydroxylation to produce 6-exo-hydroxyfenchone, 6-endo-hydroxyfenchone, and 10-hydroxyfenchone. During the metabolism of (-)-Fenchone, CYP2A6 may play a more important role than CYP2B6 .
    (-)-Fenchone
  • HY-117026
    LKY-047
    1 Publications Verification

    		 Cytochrome P450 Metabolic Disease Inflammation/Immunology
    LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC50 of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A .
    LKY-047
  • HY-W013268
    (S)-(+)-N-3-Benzylnirvanol

    (+)-N-3-Benzylnirvanol

    		 Cytochrome P450 Metabolic Disease
    (S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a Ki of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .
    (S)-(+)-N-3-Benzylnirvanol
  • HY-116862
    Dibenzylfluorescein

    DBF

    		 Cytochrome P450 Fluorescent Dye Others
    Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its Km value of 0.87-1.9 μM (Ex=485 nm，Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .
    Dibenzylfluorescein
  • HY-113739
    Desmethylcitalopram hydrochloride

    DCIT hydrochloride

    		 Cytochrome P450 Neurological Disease
    Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC50s of 39.5 and 53.5 μM .
    Desmethylcitalopram hydrochloride
  • HY-124542
    5-Hydroxydiclofenac

    		Drug Metabolite Apoptosis Cancer
    5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .
    5-Hydroxydiclofenac
  • HY-137258
    (±)-N-3-Benzylnirvanol

    		Cytochrome P450 Metabolic Disease
    (±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with Ki values of 0.25 and 5.3 μM for CYP2C19, respectively .
    (±)-N-3-Benzylnirvanol
  • HY-17356S
    Fenofibrate-d6

    		Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d6
  • HY-B1184AR
    (S)-Mephenytoin (Standard)

    (+)-Mephenytoin (Standard)

    		 Reference Standards Cytochrome P450 Neurological Disease
    (S)-Mephenytoin (Standard) is the analytical standard of (S)-Mephenytoin. This product is intended for research and analytical applications. (S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism .
    (S)-Mephenytoin (Standard)
  • HY-B0258S
    Gemfibrozil-d6

    CI-719-d6

    		 PPAR Cytochrome P450 Cardiovascular Disease Metabolic Disease
    Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil-d6
  • HY-121870
    Dimethocaine

    Larocaine

    		 Drug Derivative Cytochrome P450 Neurological Disease
    Dimethocaine (Larocaine) is a cocaine derivative and ester-type local anesthetic. Dimethocaine is metabolized by hP450 1A2, 2C19, 2D6, and 3A4 in vitro. Dimethocaine exhibits locomotor-promoting, reinforcing, and anxiogenic effects .
    Dimethocaine
  • HY-B0258R
    Gemfibrozil (Standard)
    5+ Cited Publications

    CI-719 (Standard)

    		 Reference Standards PPAR Cytochrome P450 Cardiovascular Disease Metabolic Disease Cancer
    Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil (Standard)
  • HY-17356R
    Fenofibrate (Standard)
    Maximum Cited Publications
    33 Publications Verification

    		 Reference Standards PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate (Standard)
  • HY-129923
    (R)-Omeprazole sodium

    		Cytochrome P450 Neurological Disease
    (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
    (R)-Omeprazole sodium
  • HY-W587878
    Thujopsene

    		Cytochrome P450 Pyruvate Kinase Fungal Apoptosis Insecticide Infection Cancer
    Thujopsene is the inhibitor for cytochrome P450, that inhibits CYP2B6, CYP3A4, CYP2C19, CYP2C8, CYP2C9 with IC50s of 1.3, 12.6, 13.6, 29.8, and 44.9 μM, respectively. Thujopsene binds to PKM2, inhibits the metabolism pathway of cancer cell, induces apoptosis in MKN45, thereby exhibiting antitumor efficacy. Thujopsene exhibits anti-termite and antifungal activities through autoxidation .
    Thujopsene
  • HY-Z2667
    (R)-Esomeprazole

    (R)-Omeprazole; (+)-Omeprazole

    		 Cytochrome P450 Metabolic Disease Inflammation/Immunology
    (R)-Esomeprazole ((R)-Omeprazole; (+)-Omeprazole) is an orally active cytochrome P450 2C19, CYP3A4, and CYP2C9-related metabolic modulator. (R)-Esomeprazole can be used in studies of digestive system diseases and compound metabolic interactions .
    (R)-Esomeprazole
  • HY-113739A
    (S)-Desmethylcitalopram

    (S)-DCIT

    		 Cytochrome P450 Neurological Disease
    (S)-Desmethylcitalopram is the isomer of Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6，-2C19 with IC50s of 39.5 and 53.5 μM .
    (S)-Desmethylcitalopram
  • HY-113739S1
    Desmethylcitalopram-d4 hydrochloride

    DCIT-d4 hydrochloride

    		 Cytochrome P450 Isotope-Labeled Compounds Neurological Disease
    Desmethylcitalopram-d4 hydrochloride is deuterated labeled Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC50s of 39.5 and 53.5 μM .
    Desmethylcitalopram-d4 hydrochloride
  • HY-B0258S1
    Gemfibrozil-d6-1

    CI-719-d6-1

    		 Cytochrome P450 PPAR Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease Cancer
    Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .
    Gemfibrozil-d6-1
  • HY-17356G
    Fenofibrate

    		Cytochrome P450 PPAR Autophagy Cardiovascular Disease
    Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate
  • HY-111906
    SCYX-6759

    		Cytochrome P450 Parasite Infection
    SCYX-6759 is an orally active, blood-brain barrier permeable anti-T. brucei agent. SCYX-6759 inhibits cytochrome P450 (IC50s: 30.3, 30.6, 47.4 μM for 2D6, 2C9, 2C19, respectively.) SCYX-6759 exhibits potent activity against T. b. brucei 427, T. b. rhodesiense STIB900, and T. b. gambiense STIB930, with IC50s of 0.07, 0.038 and 0.030 μg/mL, respectively .
    SCYX-6759
  • HY-W702646
    Hydroxymethyl tolperisone hydrochloride

    		Drug Metabolite Neurological Disease
    Hydroxymethyl tolperisone hydrochloride is a metabolite of Tolperisone (HY-B1139A). Hydroxymethyl tolperisone hydrochloride is formed from tolperisone primarily by the cytochrome P450 (CYP) isoform CYP2D6 and to a lesser extent by CYP2C19 and CYP1A2.
    Hydroxymethyl tolperisone hydrochloride
  • HY-179154
    α-Glucosidase-IN-101

    		Glycosidase Cytochrome P450 Metabolic Disease
    α-Glucosidase-IN-101 (Compound 13j) is an uncompetitive α-glucosidase inhibitor, with an IC50 of 120 nM. α-Glucosidase-IN-101 properly inhibits CYP1A2, CYP2C19, and CYP2C9 isoforms of cytochrome P450. α-Glucosidase-IN-101 can be used in the research of diabetes .
    α-Glucosidase-IN-101
  • HY-175169
    Urease-IN-21

    		Bacterial Urease Infection
    Urease-IN-21 (Compound 11b) is a Urease inhibitor with an IC50 of 0.12  μM. Urease-IN-21 has potent antibacterial activity against helicobacter pylori (H. pylori) and inhibitor activity against P450 enzyme (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 can be used for H. pylori infection research .
    Urease-IN-21
  • HY-19379
    E-2101

    		Cytochrome P450 Others
    E-2101 is a novel antispastic agent. E-2101 is a competitive CYP2C19 and CYP2D6 inhibitor with Ki values of 15 and 48 μM, respectively. E-2101 is metabolized by Cytochromes P450 to form monohydroxylated (M1 and M2), dihydroxylated (M3), and N-dealkylated metabolites (M4). E-2101 can be used in the research of skeletal muscle spasm .
    E-2101
  • HY-129923R
    (R)-Omeprazole sodium (Standard)

    		HBV Reference Standards Neurological Disease
    (R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
    (R)-Omeprazole sodium (Standard)
  • HY-134338R
    Ipflufenoquin (Standard)

    		Reference Standards Parasite Others
    (R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
    Ipflufenoquin (Standard)
  • HY-17356S2
    Fenofibrate-13C6

    		Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy Cardiovascular Disease
    Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-13C6
  • HY-17356S1
    Fenofibrate-d4

    		PPAR Autophagy Cytochrome P450 Cardiovascular Disease
    Fenofibrate-d4 is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .
    Fenofibrate-d4
  • HY-169119
    Antifungal agent 114

    		Cytochrome P450 Fungal Infection
    Antifungal agent 114 (Compound 19g) is an inhibitor for Cytochrome P450, that inhibits CYP1A2, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 at 10 μM. Antifungal agent 114 exhibits antifungal activity against Cryptococcus neoformans, Candida and Aspergillus, with MIC <0.0625 μg/mL. Antifungal agent 114 exhibits good metabolic stability in human liver microsomes with a half-time of 107 minutes .
    Antifungal agent 114
  • HY-148597
    FGFR-IN-10

    		FGFR Cytochrome P450 Cancer
    FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC50s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC50s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .
    FGFR-IN-10
  • HY-178786
    RET-IN-31

    		RET Potassium Channel Cytochrome P450 Cancer
    RET-IN-31 (Compound 13) is an orally active, selective RET inhibitor (IC50s: 1.4 nM, 1.9 nM, 3.8 nM for RET WT, RET V804L, RET V804M, respectively). RET-IN-31 inhibits hERG and Cytochrome P450 (IC50s: 13.6 μM, 7.9 μM, 12.8 μM, 16.9 μM, 8.9 μM, 13.0 μM for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4-M, CYP3A4-T, respectively). RET-IN-31 has anti-cancer effects against activated RET mutations and gene fusion-driven cancers .
    RET-IN-31
  • HY-182602
    KOSN 1724

    		Microtubule/Tubulin Cytochrome P450 Cancer
    KOSN 1724 is an anticancer agent. KOSN 1724 disrupts tubulin activity, stabilizes microtubules, and inhibits cancer cells proliferation. KOSN 1724 inhibits cytochrome P450 3A4, CYP2C9, and CYP2C19 activity. KOSN 1724 can be used for the research of cancer .
    KOSN 1724
  • HY-137258A
    (R)-N-3-Benzylnirvanol

    		Drug Isomer Cytochrome P450 Metabolic Disease
    (R)-N-3-Benzylnirvanol is the R-isomer of (±)-N-3-Benzylnirvanol (HY-137258). (±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with Ki values of 0.25 and 5.3 μM for CYP2C19, respectively .
    (R)-N-3-Benzylnirvanol
  • HY-175804
    M2 ion channel blocker-2

    		SARS-CoV Infection
    M2 ion channel blocker-2 (Compound 10) is a M2 channel blocker. M2 ion channel blocker-2 significantly blocks wild-type and mutant M2 (L27F and V27A) ion channels. M2 ion channel blocker-2 has potent antiviral activity against HCoV-229E (EC50: 4.7  μM in cytopathic effect) but not against influenza A virus. M2 ion channel blocker-2 has no significant inhibition of hERG and cytochrome P450 (CYP1A2, CYP2C19, and CYP3A4) activity .
    M2 ion channel blocker-2
  • HY-182538
    G-963

    		MEK Cancer
    G-963 is an allosteric inhibitor of mitogen-activated protein kinase kinase (MEK) with a MEK1 IC50 of 0.012 μM. G-963 interacts with Ser212 of MEK and exhibits potent antiproliferative activity against HCT116 colon cancer cells (EC50 = 0.120 μM) and A375 melanoma cells (EC50 = 0.025 μM). G-963 can be used for the research of colon cancer, melanoma .
    G-963

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: